CytoGen Venture Capital
Seoul, KR · Public · 2 known investors
Find your way into CytoGen Venture Capital
CytoGen Lab develops liquid biopsy technology for cancer detection through circulating tumor cell (CTC) isolation from blood samples, combining biotechnology and engineering for precision medicine applications.
Also known as CytoGen · Cytogen Inc. · 싸이토젠
Founders & leadership
Investors · 2
Company profile
researched Aug 2026CytoGen (싸이토젠, Cytogen Inc.) is a Korean company focused on liquid biopsy based on circulating tumor cells (CTCs). Its stated approach combines biotechnology with engineering to capture CTCs from blood, and its site organizes activity around Liquid Biopsy and CTC technology, R&D research areas and partners, published papers, products and services.
The product line is presented as a Liquid Biopsy System together with quality-management processes, while services span a Liquid Biopsy Platform, CTC isolation and enrichment, precision analysis services and CTC culture. Corporate information covers management philosophy, company history, family sites and contact details, and the website is offered in Korean, English and Japanese. An investor-relations section publishes regulatory disclosures and public notices.
Business model
CytoGen supplies liquid biopsy instrumentation and services: a Liquid Biopsy System product line alongside CTC isolation and enrichment, precision analysis services and CTC culture services, supported by an internal quality-management function.
Traction
Reported milestones include selection for the Ministry of Trade, Industry and Energy's national bio-industry core technology development program for a pancreatic cancer diagnostic platform, development and production of antibodies for lung cancer diagnosis, and cooperation agreements with Seoul St. Mary's Hospital Cancer Center, GI Biome for colorectal cancer therapeutics research, and Eutilex for immuno-oncology biomarker research.
Latest developments
Corporate disclosures published on the company site include a semi-annual report, a large shareholding report, a stock option grant filing, an extraordinary general meeting result, and notices relating to a small-scale merger, including availability of the merger agreement and a record date for shareholders opposing the merger.
▸Full profile — market position, technology, go-to-market, geography
Market position
CytoGen presents itself as a specialist in CTC-based liquid biopsy for cancer diagnostics, with company statements claiming leading capability in diagnosing bone-metastatic cancer.
Technology
The core technology is liquid biopsy based on circulating tumor cells, described as creating value through the convergence of biological and engineering methods to collect CTCs from blood. Reported development work includes antibodies for lung cancer diagnosis and diagnostic platform development for pancreatic cancer.
Go-to-market
The company works through partnerships and memoranda of understanding with hospitals and biotech firms, participation in government-funded national development programs, and direct provision of diagnostic and analysis services, with plans referenced for a diagnostic service launch in the United States.
Hospitals and cancer centers, biopharmaceutical and biotech partners conducting biomarker and therapeutic research, and users of precision oncology diagnostic services.
Geography
Headquartered in Korea, with offices at Gwacheon Urban Hub, Gwacheon-daero 7na-gil 60, Gwacheon, Gyeonggi Province; the corporate website is published in Korean, English and Japanese, and the company has discussed initiating diagnostic services in the United States.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Timeline · 7
launches, deals, and filingsCompany notices announced a small-scale merger, the availability of the merger agreement for inspection, and, dated 2026-07-29, a record date for receiving shareholder notices of opposition to the merger.
The company disclosed the results of an extraordinary shareholders' meeting and filed a report on the grant of stock purchase options.
CytoGen signed a business cooperation agreement with the cancer hospital of Seoul St. Mary's Hospital.
CytoGen signed a memorandum of understanding with GI Biome for joint research and development of a colorectal cancer treatment.
Eutilex and CytoGen agreed to cooperate on immuno-oncology biomarker research.
CytoGen announced it was selected as a participating company in the government's bio-industry core technology development project for a pancreatic cancer diagnostic platform.
The CTC-based liquid biopsy company announced it had developed an antibody for lung cancer diagnosis and begun production.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 1
primary sources listed
- CytoGen Venture Capitalcytogenlab.com · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does CytoGen Venture Capital do?
- Korean liquid biopsy company commercializing circulating tumor cell isolation and analysis technology for cancer diagnostics.
- Who are CytoGen Venture Capital's investors?
- CytoGen Venture Capital's investors include IMM Investment Japan, Kiwoom Investment.
- Where is CytoGen Venture Capital headquartered?
- CytoGen Venture Capital is headquartered in Seoul, KR.